SPEAKERS

  • Ana Cespedes, PhD, MBA

    Senior Vice President, Global Marketing and Strategy

    EMD Serono, a business of Merck KGaA, Darmstadt, Germany

  • Scott Murrie

    General Manager, Global Pricing

    GE Healthcare

  • Alan Crowther

    President of Global Markets

    Alliance Life Sciences

  • Slobodan Farago

    Commercial Excellence Manager MDS Europe

    BD

  • Dr. Vivian Mendonca

    Regional Director - Oncology Market Access and Pricing - EEMEA

    MSD

  • Halima Bengabrit

    Global Pricing Head of Established Products

    Sanofi

  • Photo Daniel Cho

    Daniel Cho

    Director Marketing, Global Pricing & Competitive Portfolio Analytics

    Philips Healthcare

  • Maarten Van Baelen

    Market Access Director

    Medicines for Europe

  • George Boretos

    CMO

    Cube RM

  • Gulen Desteli

    Global Pricing Manager

    GE Healthcare

  • Francis Arickx

    Advisor General - Head of Directorate - Directorate Pharmaceutical Policy

    RIZIV INAMI

  • Diar Fattah

    Associate Director of Medicines Optimisation

    NHS 

  • Richard Charter

    Head of Market Access & Pricing BD Diabetes Care EMEA

    Becton Dickinson

  • Libor Minichbauer

    Head of Pricing & Payer Pro

    Novartis Oncology Region EGM

  • Ruven Remo Eul

    Director, Life Sciences

    HighPoint Solutions

  • Luca Morreale

    Senior Manager Life Sciences

    HighPoint Solutions

  • Jörg Mahlich

    Head of Health Economics and Outcomes Research

    Janssen pharmaceutical

  • Mukarram Bhaiji

    Director, Global Pricing Strategy

    Smith & Nephew

  • Dr. Marco Penske

    Head Market Access & Healthcare Affairs

    Boehringer Ingelheim

  • Bryn Davies, MBA

    Managing Director

    Critical Insights - (Formerly GM, Syncera, Smith & Nephew Europe)

Where Pricing & Market Access Leaders Meet

The 8th annual EPP Life Sciences Pricing Forum has become the “must” go event for Pricing and Market Access senior executives and innovators, who want to learn and discuss the trends and developments in the pricing and profit optimisation area.

This year’s forum is completely re-designed to cover the most up to date pricing and market access real-world insights, trends and real case studies with information not available in any other event.

Our goal is to provide the most interactive and pioneering content forum, deeply detailed, in a setting with your industry peers where you will be able to network, learn and discuss about pricing strategy, payers’ relationships, price policy and innovative pricing tools. The forum offers 3 interactive days with workshops, expert presentations, panel sessions, roundtables discussions, a great evening event and many more networking activities.

 

Join us at Europe’s most influential pricing forum!

Download the forum brochure today to see the full speaker faculty and programme

Key themes chosen by the industry

 

Ο

Stay ahead of the game :
Examine the latest pricing trends 
and Life Science developments
  • The Pricing Evolution – Hear the latest pricing trends and developments in Life Sciences and how the future is shaping
  • Impact of blockchain technology on contracting
  • Use of Machine Learning technology for price getting
Ο

Empower
payers’ collaboration
  • Hear directly from payers how Life Sciences can engage and work successfully with payers
  • Analysis of the complexity of different payers around the world – understanding the different ways to value a drug and how pricing and market access play a crucial role
  • How to communicate the evidence to price optimization
 Ο
Optimise your strategic pricing to ensure commercial success
(Pharma & MedTech Tracks)
  •  Ensure an effective localization & indirect channel pricing strategy
  • Partnerships between the sales and pricing teams to improve profitability
  • The evolving Biosimilars landscape – key biosimilar trends and dynamics across Europe
  • The present and future for oncology pricing strategies
  • Drive optimal price setting for your portfolio
  • Hear how to create an effective risk sharing agreement and pay by performance model
  • Subscription based pricing models
 Ο
Implement innovative pricing models, contracting & tendering
(Pharma & MedTech Tracks)
  • Innovating value-based contracting models & economic models in Life Sciences
  • Indication based-pricing model – Analysis of the latest Life Science developments and implementations
  • Enhance launch sequence strategies and the timings to optimise global revenue
  • Explore how a successful outcome-based contracting can guaranty business success
  • Tender management excellence: Hear successful value-based & data-based tendering strategies
  • Gross-to net best practices and the value of applying them
  • Early price and early value assessment models
  • Insights on current Managed Entry Agreements
  • Hear how to create an effective risk sharing agreement and pay by performance model
  • Subscription based pricing models
 Ο
Embrace new technology tools & data management
  • How predicted reimbursement analytics can help you to optimise your pricing and profit strategy
  • The evolving data ecosystem: Understand how the industry is embracing Real-World Data to price optimisation
  • Transform your processes and systems to a successful pricing dynamics management
  • Pricing automation: techniques to improve the pricing offering and the incorporation of machine learning to optimize the process

Download the forum brochure today to see the full speaker faculty and programme

If you would like to be part of this amazing forum next year : please contact us: mariana.flores@pricingplatform.eu or  britt.dejager@pricingplatform.eu or just give us call +32(0)473.71.76.69


5 reasons why you should attend the EPP Life Sciences Pricing Forum in 2018 

  1. 120+ senior level executives come together for exclusive keynote presentations, innovative workshops, 2 breakouts on Pharma and MedTech, roundtables discussions and unrivalled networking to engage in high level business discussions that will shape the future of pricing and market acces
  2. The forum agenda was created together with key industry influencers to include the main industry’s challenges and opportunities
  3. 25+ Speakers delivering interactive workshops, roundtables, panel discussions and ground-breaking presentation
  4. Pharma & MedTech Breakouts: Discuss, learn and challenge both strategic and tactical topic
  5. Networking: Face-to-face conversations with top industry experts and your pricing peers during the innovative and interactive forum format – you will meet and do business with the leading industry leaders

Watch last year’s (2017) event video


Who is attending?

Every year 120+ attendees gather to discuss and reflect on the latest pricing and market access trends, learn about best business practices and meet world’s best experts in pricing and profit optimisation.

The EPP Life Sciences Pricing Forum brings together leading practitioners and experts to discuss, reflect, network and share. The forum is tailored for key stakeholders such as: Pricing, Reimbursement, Market Access, Commercial, Marketing and Sales Directors and VPs, CEOs and General Managers.

Download the forum brochure today to see the full speaker faculty and programme 

ATTENDING WITH 2+ GROUP : contact: mariana.flores@pricingplatform.eu or  britt.dejager@pricingplatform.eu or call +32(0)473.71.76.69.


This is an event you must attend!

  • 1 BUILD RELATIONSHIPS

    With more than 1000 minutes of network opportunity, you have plenty of time to connect with pricing colleagues from all over Europe.

  • 2 DISCUSS

    We stimulate an atmosphere of discussion and interaction, the best way to learn.

  • 3 LEARN FROM THE BEST

    A carefully selected speaking team of top pricing professionals, all active within your industry. No general talk, but only to-the point and useful presentations.

  • 4 REFLECT & PRACTICE

    Reflect on your key priorities and how to make it really happen !  Translate your key learnings into real change.

THE PROGRAMME

Download the forum brochure today to see the full speaker faculty and programme

03 Oct
13.00-15.30
WS 1 : Trends on implementing Real-World Evidence to price optimisation TBD - -



03 Oct
13.00-15.30
WS 2 : How machine learning boosts pricing analytics TBD - -



03 Oct
16.00-18.30
WS 3 : Innovative Contracting Models in the Medtech Industry TBD - -



03 Oct
16.00-18.30
WS 4 : Payer Contracting Framework for Global Pharma Player TBD - -



October 4th 2018
8:00-9:00 Registration and networking coffee
09.00 Welcome by EPP President & Speed Networking ! Pol Vanaerde, President - EPP

* Chairman’s Opening Remarks
* Speed Networking Session – Meet all the attendees and exchange business cards

09.14 Session 1 · Stay ahead of the game – Examine the latest pricing trends and Life Science developments
09.15 Zooming out: Improving Commercial Performance Through Strategic Pricing Ana Céspedes, PhD, MBA - Senior Vice President, Global Marketing and Strategy - EMD Serono, a business of Merck KGaA

Find out how to elevate the role of pricing throughout the organization as a key business decision vs the responsibility of only one team

* Examine how to integrate strategic pricing in core business processes, from Product Development, to Long Term Strategic Planning or annual country Operating Plans
* How to define a global governance model?
* Define how to leverage business technology systems to drive performance

09.45 The Pricing Evolution – Hear the latest pricing trends and digital developments in Life Sciences TBD

* Analysis of how the digital transformation is changing pricing
* Find out how the industry is evolving on implementing new strategies to improve profitability
* Demonstrate the value of the products not only to payers but also patients and different stakeholders
* Forecast of future pricing trends for Life Science

10.15 How to demonstrate value of your drug and manage different stakeholders Marco Dr. Penske - Head Market Access & Healthcare Affairs - Boehringer Ingelheim

* As government health budgets are very stretched & increasing pharmaceutical approvals are harder : what strategy could be implemented ?
* Value-based pricing models : Demonstrate value – and receive a fair price
* Value in the view of different stakeholders : patients, payers and doctors

11.00 Samoan Circle Session – get your point heard! Transparency of pricing across markets Multiple active speakers

Interactive format : Active participants sit surrounded by listeners.
Anyone who wants to talk may step forward to enter the inner circle. You can enter the inner circle at any time, including to stop somebody else from talking.

* Learn how to map your buying groups and achieve price transparency across markets
* Strategic pricing: How do we provide a certain price to a certain client? And avoid the risk of losing value across markets
* Communication excellence: How are we addressing the communication gap?

Hear different approaches on how companies are improving their strategy to customers

Panel list :

  • Halima Benghabrit – Global Pricing Head of Established Products – Sanofi
  • Mukarram Bhaiji – Director, Global Pricing Strategy – Smith & Nephew
  • More panelists tbc
12.00 Square logo Sanofi International reference pricing (IRP) Management Halima Benghabrit - Global Pricing Head of Established Products - Sanofi

Health Authorities around the world strive to contain costs of medicines, International Reference Pricing (IRP) is one of the key mechanisms to keep drug costs down. The WHO Collaborating Centre for Pricing and Reimbursement Policies defines IRP as: “The practice of using the price(s) of a medicine in one or several countries in order to derive a benchmark or reference price for the purposes of setting or negotiating the price of the product in a given country”. As a result, drug price in one country will influence the prices in the other countries.

* Analysis how IRP is one of the most complex constraints affecting the pharma industry and how it makes it difficult to both optimizing launch strategy and managing price erosion till after LoE
* Aim and mechanisms and management through the whole products LCM

12.30 Emerging markets – Opportunities and challenges on Market Access and Pricing Libor Minichbauer - Head of Pricing & Payer Programs - Novartis Oncology Region EGM

* Understand how these markets work, their potential and price dynamic
* Affordability programs in emerging markets

13.00 Networking lunch

Be part of our Birds of a Feather (BOF) Activity !

Make the most of your networking time during lunch, join a group of people with a common interest or area of expertise to informally work together, discuss and network. interest or area of expertise to informally work together, discuss and network.


Value Capture for Medical Technologies Richard Charter, Head of Market Access & Pricing Diabetes Care EMEA - BD

* Implementing a Value Based Healthcare framework in the EU

 

14.00 Icon EPP Java Junction Drive optimal price setting for your portfolio
PHARMA TRACK MEDTECH TRACK
The present and future for oncology pricing strategies

Understand how different assessments of value in Europe will lead to massive differences in terms of access to patients and pricing

Analysis of the perception of prices by payers and patients and how this affects our oncology pricing strategy

Dr. Vivian Mendonca – Regional Director – Oncology Access and Pricing – EMEAC (Europe, Middle East, Africa, Canada) – MSD

How to manage pricing across markets and time 

Analysis of the international industry benchmarks and how Europe can act towards managing prices across markets

Explore what economic factors could drive continuous and regular price adjustments

In the lack of guidance balance different methodologies to approach this in Europe

Discuss how currency shifts may impact price harmonization, and address different ways to balance this out

Slobodan Farago – Commercial Excellence Manager MDS Europe

Using real world evidence for making optimal pricing decision

Explore how RWE will ensure price transparency, market access and commercial success for your technology

Jörg Mahlich, Head of Health Economics and Outcomes Research, Janssen pharmaceutical

Partnerships between the sales and pricing teams to improve profitability

Getting the sales team to understand the importance of pricing

Guiding sales to set the right price for certain customers

Managing price expectation within all the internal teams

The evolving Biosimilars landscape – key biosimilar trends and dynamics –
Panorama of the multiple biosimilar products entering the market –  How the industry is shaping and key future considerationsAnalysis of key challenges about pricing biosimilars – how to convince payers and policy makers about sustainable pricing mechanismHear a successful real case study on gainsharing to increase access to biosimilar medicinesMaarten Van Baelen, Market Access Director – Medicines for Europe
Ensure an effective localization & indirect channel pricing strategy Understanding the value chain: Adjust and integrate your global strategy to the local market

Commercial pricing: examine the benefits of setting a local B2B angle pricing strategy to ensure profit optimization

Distributors Management: Design pay-for-performance schemes to ensure distributor alignment with company’s commercial strategy

Roundtables Discussion 

The present and future for oncology pricing strategies

Orphan Drugs: Learn how to set up an innovative pricing strategy for these types of drugs

The evolving Biosimilars landscape – key biosimilar trends and dynamics across Europe

Roundtables Discussion 

Effective localization & indirect channel pricing strategy

Partnerships between the sales and pricing teams to improve profitability

Drive optimal price setting for your portfolio


Session 2 · Optimise your strategic pricing to ensure commercial success
15.00 Insights and Outlook for the Biosimilars Procurement in Europe Ruven Remo Eul, Director, Life Sciences - and Luca Morreale, Senior Manager, Life Science - HighPoint Solutions

As more branded biologic therapies reach the end of patent and data-protection periods, biosimilars are being developed and approved for use. These biosimilars and therapies are expected to have an impact on the countries health care spending and should result in overall savings. However, the use of tendering to maximize the potential benefits of biosimilars has varied across Europe and the tendency from countries procurement to rely on the tendering process may be detrimental to a sustainable biosimilar landscape.

In this session, HighPoint will explore, based on real world data, what trend materialized over the last years in Europe and provide an outlook.


Session 3 – Embrace new technology tools & data management
15.30 Machine Learning: techniques to improve the pricing offering and process optimization TBA

* Equip your organisation to use machine learning and intelligent agents forstrategic pricing decisions
* Artificial Intelligence in Life Sciences: explore the potential to deliver a differentiated pricing approach
* Predictive pricing strategies in Life Sciences
* The use of machine learning to optimise quoting

16.00 Tender management & evaluation using CPQ software and Machine Learning George Boretos, CMO - Cube RM

* The benefits of a centralized system for tender information, evaluation, and management
* Learn how you can access information about past & upcoming tenders in order to better understand your market
* Use sophisticated CPQ software to prepare competitive tender responses, accurately and on time
* Use machine learning to evaluate the performance of tender proposals based on tender criteria and competitive information

16.30 Healthcare Blockchain: Smart Contracts Overview and Analysis TBA

* Find out the best practice for implementing a blockchain contracting model in your organisation
* Explore how smart contracts are a powerful tool for the healthcare sectors to record sensitive information such as patient data
* Understand how a healthcare blockchain would significantly reduce inefficiency
* Risks & Potential challenges when implementing associated with blockchain contracting

17.00 Interactive Panel Session The evolving data ecosystem: Understand how industry and payers should be embracing Real-World Evidence to price optimisation

* Learn how to create the value beyond the pill by enabling patient-centred healthcare
* See how incorporating Real-World Evidence and data analysis in early pricing development can provide commercialisation success and offer transparency
* Understanding how data analytics can influence key pricing decision making

Panel :
Maarten Van Baelen
, Market Access Director – Medicines for Europe
Jörg Mahlich, Head of Health Economics and Outcomes Research, Janssen pharmaceutical
More panelists tbc

17.30 Photo Life Sciences - Daniel Cho Pricing Management & Analytics Excellence Daniel Cho - Director Marketing, Global Pricing & Competitive Portfolio Analytics - PhilipsHealthcare

* Find out how to use analytics to help improve profitability with concrete examples
* Market deep dive and margin recovery – Hear two very powerful case studies from India and Germany
* How to apply Competitive Intelligence to gain pricing advantages

- Reflection and evening event news

Evening networking event !
October 5th 2018
9.00 Welcome coffee and opening day 2

Welcome coffee and reflections on yesterday

13.00 Value Capture for Medical Technologies Richard Charter, Head of Market Access & Pricing Diabetes Care EMEA - BD

* Implementing a Value Based Healthcare framework in the EU

 

- Innovating value-based pricing models & economic models in Life Sciences Francis Arickx - Advisor General. Head of Directorate. Directorate Pharmaceutical Polic - National Institute for Health and Disability Insurance (RIZIV INAMI)

* Risk sharing agreements & pay by performance schemes overview
* Hear real examples of these models in Europe
* The BeNeLuxA Initiative: vision, aims and results ; How can the Life Sciences industry and the government can work more effectively together


Market Access in a 2018 NHS/NICE - Challenges and Opportunities Diar Fattah - Associate Director of Medicines Optimisation - NHS

* Analysis of the NHS/NICE Changing landscape
* Find out the impact of real-world evidence
* High cost/rare disease market access impact
* Explore the outcomes-based contracting opportunities


Interactive Q&A Payers’ Interactive Q&A

Hear directly from payers their key objectives and how the industry can work successfully with them

* Understanding what is important to payers and how the industry can participate to meet payers’ aims
* What payers expect from the Life Sciences industry and what are the new rules to payers’ collaboration
* Payers Alliances: Hear the latest payers’ collaboration & common technology assessment between countries
* Analysis of the main challenges and opportunities for the Life Sciences industry and what does it mean for Pricing

Panel :
Diar Fattah – Associate Director of Medicines Optimisation – NHS
Francis Arickx – Advisor General. Head of Directorate. Directorate Pharmaceutical Policy – National Institute for Health and Disability Insurance (RIZIV INAMI)
More panelists tea


Early price and early value assessment models Scott Murrie, PhD - General Manager, Global Pricing and Gulen Desteli, Global Pricing Manager - GE Healthcare

* Find out how developing an early price and early value assessment strategy creates a comprehensive value communications strateg
* Analysis of the tools used and the results

 

 


Indication based-pricingmodel – Analysis of the latest Life Science developments and implementations

* Is indication based-pricing really working in the Life Science industry
* Industry scenario of pricing for high-value indications and low-value indications
* Accomplishments of implementing an indication-based pricing model


Pricing and profitability management strategies – Optimize yourGross-to-Net process Mukarram Bhaiji- Director, Global Pricing Strategy - Smith & Nephew

* Gross-to net best practices and the value of applying them
* Rebates & Discounts Management: Understanding where you are, what you need to improve and how to get the whole company involved
* Explore the key elements todevelop a solid commercial strategy by improving your GTN approach
* What changes you need to implement within your organisation to enhance GTN?


Enhance launch sequence strategies and the timings to optimise global revenue TBA

* Analysis of Life Sciences launch sequencing current trends
* Find out how to optimize the launch of new products to minimize the life-time impact of international reference pricing – understanding price regulations and measures
* Examples of how to launch in uncertain and complex markets
* New perspective on how to implement a launch sequence strategy – Learn what to include and what to look for


Networking lunch

Be part of our Birds of a Feather (BOF) Activity !

Make the most of your networking time during lunch, join a group of people with a common interest or area of expertise to informally work together, discuss and network. interest or area of expertise to informally work together, discuss and network. 


Icon EPP Java Junction Industry Tracks
PHARMA TRACK MEDTECH TRACK
Insights on current Managed Entry Agreements (MEAs)

Learn how to implement Managed Entry Agreements (MEAs) to achieve sustainable pricing

·Review of existing MEAs in Europe

The use of Managed Entry Agreements to achieve sustainable pricing – Hear a real case study

Tender management in MedTech – Hear successful optimisation strategies 

Tender optimization strategy – Find out the latest cost containment strategies and reimbursement for MedTech

Optimizing your tendering process with data

Getting to talk to right stakeholders for a successful commercial tender and partnership

Hear how to create an effective risk sharing agreement and pay by performance model

Hear the do’s and don’ts of a successful implementation

Analysis of the commercial impact for your organisation when executing these models

A look at the key challenges – leverage your existing capabilities to gain commercial success and become a full value-based care provider

Subscription based pricing models

Is MedTech ready to apply a subscription-based model?

Transitioning to the subscription model – Analysis of the pros and cons

Interactive Campfire
Storytelling Session

Be ready to share your own pricing experiences with others!The facilitator will introduce current pricing topics and encourage a discussion trying to reveal common issues and solutions.

Interactive Campfire
Storytelling Session

Be ready to share your own pricing experiences with others!The facilitator will introduce current pricing topics and encourage a discussion trying to reveal common issues and solutions.


Final reflections and closing
Drive optimal price setting for your portfolio

* Learn how to manage and provide a price list to customers for a big portfolio – from start to finish and managing all the deals successfully
* Understand how to boosts price execution and strategy and manage complicated metrics
* Learn how to collaborate with the commercial & board teams to get the buy-in when adding new products and make pricing as an important option for the overall operational company strategy


Session 4 · Empower payers’ collaboration

Session 5 · Implement innovative pricing models, contracting & tendering

Contact Forum Producer

Mariana Flores

PRE FORUM WORKSHOPS

Interested in delivering a Workshop ?

This can be your space to tell the industry about your innovative solutions and products.
Contact Mariana Flores : e: mariana.flores@pricingplatform.eu -/ m : +44 7792 905 223

WS 1 : Trends on implementing Real-World Evidence to price optimisation

03Oct13.00-15.30


TBD () -

MORE INFO »

SPEAKERS

We are proud to announce already a great line-up of experienced speakers for 2018 !!

If you would like to join the speaker faculty, please contact Mariana Flores: mariana.flores@pricingplatform.eu

Ana Cespedes, PhD, MBA

Senior Vice President, Global Marketing and Strategy

EMD Serono, a business of Merck KGaA, Darmstadt, Germany

Ana is a senior global leader with experience across Biotech, Pharma, Chemicals, Food and Business Consulting industries. She has successfully built and executed growth strategies focused on multi-customer models (physicians, payers, patients, policy makers), seamless cross-functional collaborations, 360-communication strategies, and implementation of digital technologies and platforms to maximize business outcomes and improve effectiveness.

She has hold numerous Country, Regional and Global leadership roles, with responsibilities over Government Affairs and Policy; Market Access and Pricing; Corporate, Brand and Digital Communications; Corporate Social Responsibility and Corporate Innovation, among other areas. Ana also has 7 years of General Management experience.  PhD in Pharmacy Magna Cum Laude and Top1 PhD Award; Master’s Degree in Management of Healthcare Institutions; and Executive Degree in General Management.

Scott Murrie

General Manager, Global Pricing

GE Healthcare

Scott is responsible for the strategic pricing of GE Healthcare’s portfolio and has over 20 years of experience in pricing.  He joined GE Healthcare in 2006 and held leadership positions in Market Access and Global Pricing.  Prior to GE, Scott served in several pricing and product management roles in the telecommunications industry.  Scott holds a PhD in Economics from Oklahoma State University and a BBA in Economics from The University of Oklahoma.  In addition, Scott completed the Oxford Strategic Leadership Program at the Saïd Business School, University of Oxford.

Alan Crowther

President of Global Markets

Alliance Life Sciences

Alan Crowther is President of Global Markets of Alliance Life Sciences, responsible for overseeing the Global Pricing solutions for Alliance. He brings 20 years of leadership, consulting and technology experience with him to the position. Alan has previously held roles as CEO at Alliance; founder of Adjility Health, a firm focused on life sciences analytical software; Vice President at Capgemini; Co-founder and Officer at Adjoined Consulting, where he ran the Life Sciences practice and was part of the leadership of the venture-backed company and helped drive it to a successful $200MM+ exit. Prior to Adjoined, Mr. Crowther was head of services for a small software company that exited to BEA Systems; and was a manager at Andersen Consulting (Accenture) before that. He is a graduate of Princeton University.

 

Slobodan Farago

Commercial Excellence Manager MDS Europe

BD

20 years plus of business and team leadership experience in life sciences (Life Sciences/Pharmaceuticals/Diagnostics/MedTech/Biotech). Well-proven in strategic roles (HQ) with leading industry players and consulting agencies. Value and solution driven mindset. Education background in biological sciences, management and business administration, and pricing. Strong expertise in Commercial Excellence, Sales Force Effectiveness, Business Analytics, Strategic Pricing, Marketing. People management and team leadership routine.

Dr. Vivian Mendonca

Regional Director - Oncology Market Access and Pricing - EEMEA

MSD

Halima Bengabrit

Global Pricing Head of Established Products

Sanofi

With more than 20 years’ experience in the pharma industry, Halima worked for several European and US companies. She has an extensive experience in marketing, mainly in cardio-vascular, CHC and diabetes areas at country and global level.  She moved 7 years ago to a global market access role before heading market access for emerging markets.

Currently Halima is leading global pricing management for established products. Her team is also in charge of implementing a new global price management tool deployed WW for the whole Sanofi portfolio as well as developing pricing analytics to optimize pricing execution and visibility.

Photo Daniel Cho

Daniel Cho

Director Marketing, Global Pricing & Competitive Portfolio Analytics

Philips Healthcare

Daniel is the head of a Global Pricing team of 10 which spans in USAndover and Germany Boeblingen, serving the business need forusing pricing as a tool to optimize margin and profitability for a 2.7BEuro business with Philips Healthcare. Daniel and his team built anextensive BI platform based on the Qlikview platform and provide1500+ users daily access to actionable intelligence from CRM (SF.com), OIT, Sales, Margin, Pricing (From SOFON Quotation system+ SAP) and other business data such as Installed Base. Daniel andteam have proven records of reversing the price erosion for all business,helping to improve market business margins within one-year cycle, aswell as improving qualified funnels for high margin business within aquarter. Daniel also had global experience in Product Management,Market Intelligence, New Product Introduction, as well as SalesDevelopment for Asia Pacific and Sales & Marketing experiencefor Asia Pacific. Daniel was also a trained Management Consultantfrom PriceWaterhouse in Sydney. He is now located in BoeblingenGermany for the past 14 years.

Maarten Van Baelen

Market Access Director

Medicines for Europe

The goal of « Medicines for Europe » (formerly EGA) is to improve health by ensuring better access to treatment for patients in Europe and beyond.  As Market Access Director, the objective of Maarten’s team is to shape in the EU a dynamic and sustainable market situation that enables fast and fair pricing and reimbursement for generic, biosimilar and value-added medicines.

Maarten joined « Medicines for Europe » in 2011 as Medical Affairs Manager with responsibilities in the areas of fighting Falsified Medicines and Pharmacovigilance. In his life before the association, he worked in the pharmaceutical industry providing pharmacovigilance consultancy and in the medical device industry liaising with Key Opinion Leaders. He combined these roles while working weekends in a community pharmacy.

Maarten is a pharmacist by education and holds an MBA from “Solvay Brussels School of Economics and Management” and “École des Ponts Paris Business School”.

George Boretos

CMO

Cube RM

George is the CMO of Cube RM, a vendor of Revenue Management & Optimization solutions with specialization in CPQ software. He has more than twenty years of professional experience in managerial positions in product marketing, pricing, corporate strategy, and sales. He is also a seasoned data scientist, specialized in price optimization models, with numerous successful business forecasts and scientific publications to his name in prestigious scientific journals and publishers, such as Elsevier and Foresight. He is a member of the International Institute of Forecasters

Gulen Desteli

Global Pricing Manager

GE Healthcare

Gulen Desteli works as a Global Pricing Manager at GE Healthcare and leads global pricing initiatives to drive profitability in complex markets and institutionalize value based pricing. Desteli is a seasoned pricing professional with 12 years of strategic pricing experience in Healthcare, FMCG, Telecom and Software industries. She holds an MBA from the University of Virginia, Darden School of Business and an undergraduate degree in Economics from Bogaziçi University.

Francis Arickx

Advisor General - Head of Directorate - Directorate Pharmaceutical Policy

RIZIV INAMI

Francis Arickx is the head of the directorate Reimbursement of Medicines and Pharmaceutical Policy within the Health Care Department at the National Institute for Health and Disability Insurance (NIHDI RIZIV/INAMI) in Belgium where he manages the departments responsible for administrative and scientific assessment and appraisal of reimbursement claims for medicines, orphan drugs, medical nutrition,…

Francis Arickx is the former secretary general for the Commission for Reimbursement of Medicines and acts as representative/expert for the Institute and Belgium on a number of national and European platforms (NM CAPR, MEDEV, MoCA,..). He is one of the country coordinators for the BeNeLuxA Initiative (www.beneluxa.org).

Francis graduated in pharmaceutical sciences from the University of Ghent, Belgium and teaches ‘Health Policy’ in the Pharmaceutical Sciences Department at the University of Antwerp.

Diar Fattah

Associate Director of Medicines Optimisation

NHS 

A pharmacist and health economist, Diar leads on medicines use and optimisation, prescribing and the provision of pharmaceutical services within the Dartford, Gravesham & Swanley CCG. In addition, he sits on the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee.  His work has been focused on combatting inappropriate polypharmacy with the use of healthcare data analytics.

Richard Charter

Head of Market Access & Pricing BD Diabetes Care EMEA

Becton Dickinson

Richard is currently the Head of Market Access & Pricing at Becton Dickinson (BD) EMEA, for the Diabetes Care franchise. He is also vice-Chair of the MedTech Europe ‘Evidence & Payers’ Working Group.  Richard is also a core contributor to the MedTech Europe EU Value based Procurement Working group, as well as co-Chair of the ISPOR Medical Device Special Interest Group. Within these roles, Richard is focused on creating pragmatic, win-win patient access solutions in value based healthcare that align payers and manufacturers around outcomes based frameworks.

Richard currently lives in Switzerland, and graduated as class valedictorian from Bocconi University in Italy, with a Masters in Healthcare Management Economics and Policy (the MIHMEP program), and an undergraduate degree in Management Economics and Public Policy from the University of Guelph, Canada in 2002.

Libor Minichbauer

Head of Pricing & Payer Pro

Novartis Oncology Region EGM

Libor Minichbauer is heading pricing for Novartis Oncology Emerging Growth Markets unit. In his current role he is responsible for pricing and innovative pricing models in 80+ countries in Asia, Middle East, Africa and CIS. Libor has worked in the industry for the last 10 years, held various roles in development, health economics, and pricing. Prior to joining pharma, he has spent several years in consulting, and IT and finance industries. Libor obtained his MBA from DePaul University in Chicago. He also holds a Masters in International Trade and Diplomacy from the University of Economics in Prague and Masters in Pharmacoeconomics from Pompeu Fabra University in Barcelona.

 

Ruven Remo Eul

Director, Life Sciences

HighPoint Solutions

Ruven is a Director within the European Life Sciences team based out of Zug, Switzerland responsible for project oversight and delivery, resource management and solution development in the areas of Pricing, Contracting and Tendering. Ruven brings a background of industry experiences in large pharma from companies such as Pfizer and BMS where he worked in Commercial roles with a large focus on leading cross functional Tendering teams for Pfizer in Germany. While at HighPoint Solutions, Ruven has worked with emerging, mid-tier and large pharma on various Tendering and Contracting programs from policy and process assessments, outsourcing of business functions, software vendor evaluations and implementation of global programs. Additionally, Ruven has conducted the industry’s first Benchmarking Study on Tendering issuing 4 reports presenting the benchmarking results and developed HighPoint’s Tender Data Service THOR focusing on supporting the awareness & planning phase of Tendering while building Competitive and Pricing Intelligence. In parallel, Ruven has also worked deeply in global commercial effectiveness programs.

Luca Morreale

Senior Manager Life Sciences

HighPoint Solutions

Luca is a Senior Manager supporting the European Life Sciences team based out of Geneva, Switzerland assisting clients from Big Pharma, Med Device to Mid and Emerging Pharma as relates to Pricing, Contracting and Tendering Strategy, Operations, and Technology.
• Project Manager in the areas of Commercial Excellence, Pricing, Contracting and Tendering
• SME involved in multiple implementations of Tendering, Contracting, GPM, CRM, Business Intelligence as well as territory alignment tools.
• Business analysis, quality assurance and project management for a range of technology platform ranging from Salesforce, Veeva Vault to SharePoint or Model N Flex.
• Led and published the first major industry benchmarking study on Tendering within Life Sciences.

Jörg Mahlich

Head of Health Economics and Outcomes Research

Janssen pharmaceutical

Jörg Mahlich is head of Health Economics and Outcomes Research at Janssen pharmaceutical companies of Johnson and Johnson in Germany. In addition, he is lecturer of Health Economics at the Economics Department of the University of Vienna and research affiliate at the Düsseldorf Institute for Competition Economics (DICE) of the University of Düsseldorf, Germany. Previous to that he hold different positions in industry and consulting in Austria, Germany, and Japan. He is interested in global pharmaceutical economics and policy. Jörg graduated in economics from the University of Kiel, Germany and holds a doctoral degree in economics from the University of Vienna, Austria.

Mukarram Bhaiji

Director, Global Pricing Strategy

Smith & Nephew

Responsible for designing pricing strategy, policies and governance for Smith & Nephew globally.

Dr. Marco Penske

Head Market Access & Healthcare Affairs

Boehringer Ingelheim

Dr. Marco Penske has been the Head of Market Access and Healthcare Affairs of Boehringer Ingelheim since 2011.

Dr. Marco Penske has studied Economics at the University of Mainz with focus on Health Economics and Statistics. Afterwards, he was working as a Research Assistant at the chair of Finance and Economics at the same university. After his promotion about questions of financing healthcare systems and the expansion of capital covered elements, he was employed at a business consultancy company. In 2007 he has joined Boehringer Ingelheim. His current responsibilities are among others the benefit assessment and price negotiation after AMNOG, the development of pricing strategies and contract models for pharmaceuticals and the healthcare affairs activities. Moreover, he is an active speaker on congresses and working as a lecturer.

Bryn Davies, MBA

Managing Director

Critical Insights - (Formerly GM, Syncera, Smith & Nephew Europe)

My vision is for everyone to have access to safe healthcare. In particular, safer surgical care. This means harnessing the potential of digital technology to address the shortage of human expertise that exists today.  It is incumbent on us to find solutions that solve these answers in a cost-effective and scalable way. To achieve this, we all need to play our part.  For me this is to work with early stage digital health technology companies together with the medical device industry to help the transformation of how solutions are provided to healthcare providers.  Shifting the traditional mindset of a product led $500Bn industry (Forbes).

I have worked in commercial medical devices for over 16 years.  Developing from sales representative, to a business leader responsible for the $300M commercial operations of the business at Smith & Nephew UK& I.   More recently I was the European leader in business model innovation, evaluating and selecting digital health technologies to deliver new value propositions and solutions for healthcare providers.   Now, having left the corporate world I am working on the commercialisation, market access and business development of start-up and early stage digital health tech companies.

 

TESTIMONIALS

Fresenius-Kabi SwissBioSim

Sue Caleo-Naeyaert, Global Head Pricing, Market Access and Policy Biosimilars at Fresenius-Kabi SwissBioSim

“This is a great conference which covers most pricing topics with a decent amount of detail. Anyone can benefit from this conference no matter how experienced”

Ian Tidswell

Ian Tidswell, Founder and Lead Consultant at een Consulting GmbH

The EPP Life Sciences Pricing Forum is a unique event for learning about the latest pricing challenges and techniques to address them, due to the deep experiences and skills of the participants and speakers

BTG

Giuseppe Monita , Senior Manager, Customer Services Contracts & Tendering EMEA at BTG

“Exciting & energetic meeting where it is possible to learn, share & discuss best practices and new ideas on hot topics regarding pricing & tendering” 

Cogentia Healthcare Consulting

David Alderson, Director at Cogentia Healthcare Consulting

“A good event for catching up, great networking and opportunity to share current thinking and best practice” 

Bayer

Henderson Azevedo, Global Pricing Oncology at Bayer

“A highly recommended forum for pricing professionals”

Tefen Management Consulting

Chiara Garavaglia, Partner, Global Leader of Tefen Life Sciences Centre of Excellence & Innovation at Tefen Management Consulting

“In my experience, EEP is the only existing opportunity to discuss at 360 degrees about Pricing, involving both pharmaceutical and med tech stakeholders”

Sue Caleo-Naeyaert

Sue Caleo-Naeyaert , Global Head Pricing, Market Access and Policy Biosimilars at Fresenius-Kabi SwissBioSim

“This is a great conference which covers most pricing topics with a decent amount of detail.   Anyone can benefit from this conference no matter how experienced”

 

Henderson Azevedo

Henderson Azevedo, Global Pricing Oncology at Bayer

“A highly recommended forum for pricing professionals”

Alan Crowther

Alan Crowther, President, Global Markets at Alliance Life Sciences Consulting Group

“The 7th EPP Life Sciences Pricing Forum was the 3rd in a row that Alliance Life Sciences attended.  This year’s conference was the best yet in content. Participants come prepared to learn, share and together they helped shape the trends in our industry. The forum on the shores of Lake Geneva at the foot of the Alps is also the best locale you can imagine for a thought-provoking, content-rich conference. What a great atmosphere!”

Chiara Garavaglia

Chiara Garavaglia, Partner, Global Leader at Tefen Management Consulting

“In my experience, EEP is the only existing opportunity to discuss at 360 degrees about Pricing, involving both pharmaceutical and med tech stakeholders”

BD

, at BD

Baxter Healthcare

, at

AstraZeneca

, at

Aliaxis

, at

Fresenius

, at

GSK

, at

Merck

, at

Novo Nordisk

, at

Pfizer

, at

Meet pricing decision makers from:

VENUE

Grand Hotel Suisse Majestic – 4*deluxe

This majestic hotel was originally built during the Belle Epoque in 1870 and entirely renovated in 2010. The hotel is just on the lakefront and so you get a phenomenal view of the lake, the promenade, the gardens and of course the snow capped mountains.   Take a look at this splendid hotel !

Please note that we have a limited number of rooms at preferred rates at our disposal : contact Britt Dejager on britt.dejager@pricingplatform.eu to book now !

Avenue des Alpes 45, 1820 Montreux, Zwitserland- +41 21 966 33 33 – hotel website

The easiest way to get to Montreux is to take the train from Geneva Airport direct to Montreux (CHF 35.-/ 2nd class and CHF 62.-/ 1st class)
There is a direct train every 20 minutes (http://www.sbb.ch/en/timetable.html ) – the hotel is straight across the train station.
A taxi will be about CHF 350.-

Photo Grand Hotel Suisse Majestic

Snow capped mountains…

Grand Hotel Suisse Majestic5

…with a great view to the lake…

Grand Hotel Suisse Majestic3

…all comfort in the Belle Epoque…

P1180175

Share, learn and discuss

Grand Hotel Suisse Majestic4

…in an inspiring environment.

P1180607

Perfect work-pleasure combination!

CONTENT

Financial Assessment of Managed Entry Agreements

New types of contracting options are explored to address the respective expectations of payers and manufacturers. Binding discounts to conditions is the solution proposed by Managed Entry Agreements (MEAs).

The evolving biosimilars landscape

Observations and key considerations for biopharma companies.

Operational Pharma Pricing Benchmark Summary Findings

A 2018 pricing benchmark survey conducted by Alliance Life Sciences Consulting  Group.

Download exclusive presentations about pricing trends and benchmarks on :

  • Operational Pricing
  • The Evolving Biosimilars Landscape
  • Managed Entry Agreements

These presentations cover the latest pricing insights, trends and benchmarking information with detailed and unique insights, conducted by industry leading experts supported by primary market and global research compiled from dozens of sources.

We hope you enjoy the content. All these topics will be covered in this year’s 8th EPP Life Science Pricing Forum : Register today to secure your place.

EPP PARTNERSHIPS

For more info please contact Britt.dejager@pricingplatform.eu

REGISTRATION

Register Today & SAVE €400 – Super Early Bird Discount!

• EPP Members benefit from our preferred membership rates – not yet a member ? Discover all EPP member benefits here 
• Once a registration is completed, tickets are transferable but never refundable. This applies to payments via invoice as well.

FULL CONFERENCE

1595
SAVE € 400 WITH SUPER EARLY BIRD !
EXPIRES 13TH JULY!
NORMAL PRICE € 1995
3-4-5 OCT
Access to workshops
Access to 2 forum days
Access to evening event Oct 4th
PDF presentations after event

BUY 2 GET 1 FREE

3990
SAVE € 1995 WITH THIS PASS
2 FULL PASS +1 FREE
 
3-4-5 OCT
Access to workshops
Access to 2 forum days
Access to evening event Oct 4th
PDF presentations after event

FORUM PASS ONLY

1295
SAVE € 400 WITH SUPER EARLY BIRD !
EXPIRES 13TH JULY!
NORMAL PRICE € 1695
4-5 OCT
 
Access to 2 forum days
Access to evening event Oct 4th
PDF presentations after event

BUY 2 GET 1 FREE

3390
SAVE € 1695 WITH THIS PASS
2 PASSES +1 FREE
 
4-5 OCT
 
Access to 2 forum days
Access to evening event Oct 4th
PDF presentations after event

WORKSHOPS ONLY

645
WORKSHOPS ONLY PASS
 
 
3 OCT
Access to workshops
 
 
PDF workshop presentations

Group discounts are available of > 3 people
Inquire

EXPERT FORUM PASS

2995
4-5 OCT
Access to the 2 forum days
Access to evening event
PDF presentations after event

GROUP RATES

on demand
Group discounts of > 2 people